Please assess the completion status of the following clinical trial:

Trial Title: A Pharmacodynamic Study Comparing Prasugrel Versus Ticagrelor in Patients Undergoing PCI With CYP2C19 Loss-of-function:

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
* Inclusion criteria:~  1. Patients scheduled for left heart catheterization and undergoing PCI~ 2. Age 18-75 years~ 3. On aspirin (81mg) or aspirin (81mg) and clopidogrel (75mg/day)~ 4. Presence of at least one 2C19 LOF allele~* Exclusion criteria:~  1. Known allergies to aspirin, prasugrel, ticagrelor, or clopidogrel~ 2. Age \>75 years~ 3. Weight \<60kg~ 4. Considered at high risk for bleeding~ 5. History of ischemic or hemorrhagic stroke or transient ischemic attack~ 6. Known severe hepatic dysfunction~ 7. On treatment with oral anticoagulant therapy (Vitamin K antagonists, dabigatran, apixaban, rivaroxaban)~ 8. Use of glycoprotein IIb/IIIa inhibitors (abciximab, eptifibatide, tirofiban)~ 9. Blood dyscrasia or bleeding diathesis~ 10. Platelet count \<80x106/mL~ 11. Hemoglobin \<10 g/dL.~ 12. Active bleeding or hemodynamic instability~ 13. Creatinine Clearance \<30 mL/minute~ 14. Patients with sick sinus syndrome (SSS) or high degree AV block without pacemaker protection.~ 15. Current treatment with drugs interfering with CYP3A4 metabolism (to avoid interaction with Ticagrelor): Ketoconazole, itraconazole, voriconazole, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir, and telithromizycin.~ 16. Pregnant females\* \*Women of childbearing age must use reliable birth control (i.e. oral contraceptives) while participating in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 74 Years
- Healthy Volunteers: f

Study Arms:
- Ticagrelor (Type: ACTIVE_COMPARATOR): The primary endpoint is the non-inferiority in platelet reactivity of prasugrel versus ticagrelor among CYP2C19 loss of function allele carriers.
- Prasugrel (Type: EXPERIMENTAL): The primary endpoint is the non-inferiority in platelet reactivity of prasugrel versus ticagrelor among CYP2C19 loss of function allele carriers.

Based on this trial design, predict the completion outcome and termination type (if applicable).